Company Analysis

Lantern Pharma Inc. (LTRN)

Nasdaq: LTRN · Pharmaceutical Preparations · Dallas, TX · filing with the SEC since 2019
Grade5.5
◀ Past 6.0● Present 5.3▶ Future 5.4
6 est.

Who runs Lantern Pharma Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Sharma Panna
President & CEO. First filing Jun 2020, latest Sep 23, 2025, 0 filings in all.
Officers reporting now
3
of 8 people with a filing in the last fifteen months
Directors reporting now
5
10 people on the record since 2020
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Margrave David R.Chief Financial OfficerJun 2020Dec 22, 2025none
Bhatia Kishor G.Chief Scientific OfficerJun 2020Dec 22, 2025none
Sharma PannaPresident & CEOJun 2020Sep 23, 2025none
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Keyser D JeffreydirectorJun 2020May 14, 2026none
Schalop Lee TroydirectorJul 2025May 14, 2026none
Chandru VijaydirectorJun 2020Jan 13, 2026none
Maccecchini Maria-LuisadirectorJun 2022Jan 13, 2026none
Silberstein David S.directorJun 2020Jan 13, 2026none
Earlier names on the record22, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton LTRN · research, not advice